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Abstract
Objective: The objective of the study was to determine the association between proton-pump inhibitors 
(PPIs) and gallbladder (GB) function. Methods: A systematic search of Medline, EMBASE, and CENTRAL 
(inception to April 2020) was conducted to capture the relevant studies. A comprehensive inclusion-
exclusion criterion was developed and implemented to screen the titles and abstracts. Full texts of the 
selected abstracts were then appraised to establish their inclusion or exclusion in our review. The primary 
outcome was GB ejection fraction. We intended to extract study data from eligible studies into a data 
extraction form and evaluate the quality of the included studies using the best available guidelines for each 
study design outlined in the library for health research reporting. We, however, found no eligible studies. 
Results: The systematic search identified 38 unique articles for title and abstract screening. Of which, five 
were included as potentially relevant studies. However, upon full-text screening, none of them met our 
inclusion criteria. This review is, therefore, an empty systematic review. Conclusion: There are no good 
quality studies determining the effect of PPIs on GB function. Given the common use of PPIs and their 
potential impact on GB function, there is an urgent need for conducting clinical studies to address this gap 
in the evidence.
Keywords: Gallbladder ejection fraction, Gallbladder emptying rate, Gallbladder function, Proton-pump 
inhibitors
Introduction
Gallbladder (GB) disease is one of the most common 
illnesses of the digestive system around the globe 
and is a significant source of the economic drain 
in many nations.[1] Patients with intermittent right 
upper quadrant (RUQ) abdominal pain generally 
undergo an ultrasound to rule out gallstones. 
However, hepatobiliary iminodiacetic acid scan 
(HIDA) with cholecystokinin stimulation is used to 
assess the function of the GB and biliary tree, if 
the diagnosis could not be formed by ultrasound. 
HIDA scan measures GB emptying rate also called 
ejection fraction of the GB (GBEF). An accepted 
normal functioning GBEF is >35% and typically 
ranges between 35% and 65%. However, an ejection 
fraction below 35% indicates GB motility disorder 
called biliary dyskinesia or hypokinesia of the GB.[2]
The human liver produces at least 1000 ml of bile 
per day, but standard bile duct flow rates are low 
during fasting (0.5–1.0 ml/min), they increase after 
a meal to between 2 and 3 ml/min.[3] The inability of 
GB to release bile into the small intestine not only 
affects fats digestion but also irritates GB walls. 
This irritation results in inflammation which causes 
a majority of GB diseases, including cholecystitis 
and gallstones.[4] Hence, GBEF is one of the primary 
tests to understand GB disorders.
Health practitioners use various tests to form the 
diagnosis. The widely accepted diagnosis of biliary 
dyskinesia is comprised of vague RUQ pain in the 
absence of gallstones or with GB wall thickening 
and an abnormally low GBEF on HIDA scan. This 
scan shows the movement of the bile through the 
bile duct system and measures the GB emptying 
rate.[5]
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Proton-pump inhibitors (PPIs) are a group of 
medications that reduce the production of stomach 
acid. PPIs are largely used to treat symptoms 
of gastroesophageal reflux disease (GERD) and 
are considered the most effective treatment of 
GERD.[6] Morton et al. (2002) conducted a study to 
compare pre- and post-operative GB function in 
patients undergoing fundoplication to understand 
the association between GERD or its therapies and 
GB function. The authors unexpectedly found that 
approximately 60% of patients with pre-operative GER 
had abnormally low GB function. More surprisingly, 
86% of these patients had normalized GB function 
after fundoplication.[7] This discovery led Cahan et al. 
(2006) to conduct a trial to determine whether GB 
function is reduced by chronic PPI therapy. Although 
the authors found some evidence to support their 
hypothesis, this evidence alone may be insufficient 
to determine the direct associations between PPIs 
and GB function. There is no systematic review to 
summarize the evidence on the association between 
GB function and PPIs. We are, therefore, conducting 
this systematic review to identify the studies 
indicating the association PPIs and GB function.
Objectives
There were two objectives of this systematic review:
•	 To determine the association between PPIs and 
GB function
• To highlight the gap in the evidence.
Methods
This systematic review was conducted to summarize 
the evidence describing the effect of PPIs on GB 
function. We followed PRISMA reporting guidelines 
(Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses) for this systematic literature 
review.[8] We aimed to apply a rigorous and 
transparent methodology to reduce bias in the 
selection of relevant studies.
Criteria for considering studies for this review
Eligibility criteria
Eligibility criteria for including studies for this 
systematic literature review were as follows:
Type of studies
All published randomized and non-randomized 
clinical trials, including cluster and cross-over 
trials, were eligible for inclusion in this systematic 
review. In addition to this, analytical observational 
studies including prospective and retrospective 
cohort studies, prospective and retrospective case–
control studies, cross-sectional studies, controlled 
before-and-after studies, and systematic reviews 
were also eligible for inclusion. Systematic reviews 
were included for cross-referencing. We, however, 
excluded single-arm studies, letters to the editor, 
narrative reviews, editorials, expert opinions, case 
studies, and case series.
Minimum study duration
Studies of any duration were eligible for inclusion in 
this systematic review.
Publication language
Studies published in English language were eligible 
for inclusion in this review.
Types of participants
Studies conducted in any population were included 
in this review without any restrictions.
No age limits were applied.
Types of interventions
Studies comparing the effect of PPIs and placebo 
or any other intervention on GBEF and GB function 
were included in this systematic review.
Outcomes
The primary outcome was GBEF. The secondary 
outcomes were any abnormal functioning of GB 
due to the effect of PPIs.
Data sources and search strategy
We systematically searched three databases; 
Medline, EMBASE, and Cochrane Central Register 
of Controlled Trials (CENTRAL) for this review. 
Medline and EMBASE were searched through 
ProQuest while CENTRAL was searched through 
Cochrane library. All three databases were 
searched from inception to April 2020 to retrieve 
the relevant literature. Our core search strategy 
was based on the keywords extracted from 
relevant articles, Medical Subject Headings, and 
the controlled vocabulary used by each database. 
The search strategy used for Medline, EMBASE, 
and Cochrane is reported in the Supplementary 
Materials [Table 1] and was constructed from 
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Set# Searched for Databases Results
S1 (MESH.EXACT.EXPLODE(“Gallbladder Emptying”)) MEDLINE® 717°
S2 (ti,ab(“gallbladder ejection fraction“ or “GBEF“ or “gallbladder function“ or 
“gallbladder motor dysfunction“ or “gallbladder motor function“ or “gallbladder 
disorder“ or “gallbladder disorders“ or “gallbladder disease“ or “gallbladder 
problem“ or “gallbladder emptying“ or “gallbladder“))
MEDLINE® 32145*
S3 (MESH.EXACT.EXPLODE(“Biliary Dyskinesia“)) MEDLINE® 1240°
S4 (ti,ab(“biliary dyskinesia“ or “gallbladder spasm“ or “chronic acalculous 
cholecystitis“))
MEDLINE® 541°
S5 S4 OR S3 OR S2 OR S1 MEDLINE® 32256*
S6 ((MESH.EXACT.EXPLODE(“Proton-Pump Inhibitors”))) MEDLINE® 18623*
S7 (ti,ab(“omeprazole” or “Prilosec” or “Prilosec OTC” or “aspirin and 
omeprazole” or “Yosprala” or “lansoprazole” or “Prevacid” or “Prevacid IV” 
or “Prevacid 24-h” or “dexlansoprazole” or “Dexilent” or “Dexilent Solutab” 
or “rabeprazole” or “Aciphex” or “Aciphex Sprinkle” or “pantoprazole” or 
“Protonix” or “esomeprazole” or “Nexium” or “Nexium IV” or “Nexium 24 HR” 
or “esomeprazole magnesium” or “naproxen” or “Vimovo” or “omeprazole” or 
“sodium bicarbonate” or “Zegerid” or “Zegerid OTC” or “proton-pump inhibitor” 
or “proton-pump inhibitors” or “PPI” or “PPIs” or “antisecretory agents” or 
“antisecretory”))
MEDLINE® 50012*
S8 S7 OR S6 MEDLINE® 53972*
S9 ((MESH.EXACT(“clinical trial (topic)”) OR MESH.EXACT(“controlled clinical 
trial”) OR MESH.EXACT(“clinical trial”) OR MESH.EXACT(“controlled clinical trial 
(topic)”) OR MESH.EXACT(“cohort analysis”) OR MESH.EXACT(“population-based 
case–control study”) OR MESH.EXACT(“hospital-based case–control study”) OR 
MESH.EXACT(“case–control study”) OR MESH.EXACT(“multicenter study (topic)”) 
OR MESH.EXACT(“multicenter study”) OR MESH.EXACT(“retrospective study”) 
OR MESH.EXACT(“systematic review (topic)”) OR MESH.EXACT(“systematic 
review”) OR MESH.EXACT(“meta-analysis”) OR MESH.EXACT(“meta-analysis 
(topic)”) OR MESH.EXACT(“prospective study”)) OR (ti,ab(“randomized 
controlled trial” or “randomized controlled trial” or “randomization” or 
“randomization” or “randomized control*” or “rct” or “single blind*” or 
“double blind*”) or ti,ab((single OR double OR treb$ OR tripl$) NEAR/2 (blind* 
OR mask)) or ti,ab(“phase 1 clinical trial” or “phase 2 clinical trial” or “phase 
3 clinical trial” or “phase 4 clinical trial”) or ti,ab(“phase 1” or “phase 1” or 
“phase ii” or “phase 2” or “phase iii” or “phase 3” or “phase iv” or “phase 4”) 
or ti,ab(allocat* NEAR/3 random*) or ti,ab(random* NEAR/4 (trial* OR stud*)) 
or ti,ab(“clinical trial” or “meta-analysis” or “multicenter study” or “multicenter 
study” or “prospective study”))) NOT ((MESH.EXACT(“case study”)) OR MESH.
EXACT(“letter”) OR MESH.EXACT(“editorial”) OR (ti,ab(“case study” or “letter” or 
“editorial”)))
MEDLINE® 1016780*
S10 (S8 AND S9 AND S5) and (human(yes)) and (la.exact(“English”)) MEDLINE® 7°
S11 ((EMB.EXACT.EXPLODE(“gallbladder emptying”))) EMBASE® 837°
S12 ((ti,ab(“gallbladder ejection fraction” or “GBEF” or “gallbladder function” or 
“gallbladder motor dysfunction” or “gallbladder motor function” or “gallbladder 
disorder” or “gallbladder disorders” or “gallbladder disease” or “gallbladder 
problem” or “gallbladder emptying” or “gallbladder”)))
EMBASE® 44790*
S13 (EMB.EXACT.EXPLODE(“Biliary Dyskinesia”)) EMBASE® 4°
S14 (ti,ab(“biliary dyskinesia” or “gallbladder spasm” or “chronic acalculous 
cholecystitis”))
EMBASE® 747°
Table 1: Search strategy for Medline and EMBASE
(Contd...)
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Set# Searched for Databases Results
S15 S11 OR S12 OR S13 OR S14 EMBASE® 45400*
S16 ((EMB.EXACT.EXPLODE(“proton-pump inhibitor”))) EMBASE® 78283*
S17 (((ti,ab(“omeprazole” or “Prilosec” or “Prilosec OTC” or “aspirin and 
omeprazole” or “Yosprala” or “lansoprazole” or “Prevacid” or “Prevacid IV” 
or “Prevacid 24-h” or “dexlansoprazole” or “Dexilent” or “Dexilent Solutab” 
or “rabeprazole” or “Aciphex” or “Aciphex Sprinkle” or “pantoprazole” or 
“Protonix” or “esomeprazole” or “Nexium” or “Nexium IV” or “Nexium 24 HR” 
or “esomeprazole magnesium” or “naproxen” or “Vimovo” or “omeprazole” or 
“sodium bicarbonate” or “Zegerid” or “Zegerid OTC” or “proton-pump inhibitor” 
or “proton-pump inhibitors” or “PPI” or “PPIs” or “antisecretory agents” or 
“antisecretory”))))
EMBASE® 77510*
S18 S17 OR S16 EMBASE® 118411*
S19 (EMB.EXACT(“clinical trial (topic)”) OR EMB.EXACT(“controlled clinical trial”) 
OR EMB.EXACT(“clinical trial”) OR EMB.EXACT(“controlled clinical trial (topic)”) 
OR EMB.EXACT(“cohort analysis”) OR EMB.EXACT(“population-based case–
control study”) OR EMB.EXACT(“hospital-based case–control study”) OR EMB.
EXACT(“case–control study”) OR EMB.EXACT(“multicenter study (topic)”) OR 
EMB.EXACT(“multicenter study”) OR EMB.EXACT(“retrospective study”) OR 
EMB.EXACT(“systematic review (topic)”) OR EMB.EXACT(“systematic review”) 
OR EMB.EXACT(“meta-analysis”) OR EMB.EXACT(“meta-analysis (topic)”) OR 
EMB.EXACT(“prospective study”)) OR (ti,ab(“randomized controlled trial” 
or “randomized controlled trial” or “randomization” or “randomization” 
or “randomized control*” or “rct” or “single blind*” or “double blind*”) or 
ti,ab((single OR double OR treb$ OR tripl$) NEAR/2 (blind* OR mask)) or 
ti,ab(“phase 1 clinical trial” or “phase 2 clinical trial” or “phase 3 clinical trial” or 
“phase 4 clinical trial”) or ti,ab(“phase 1” or “phase i” or “phase ii” or “phase 2” 
or “phase iii” or “phase 3” or “phase iv” or “phase 4”) or ti,ab(allocat* NEAR/3 
random*) or ti,ab(random* NEAR/4 (trial* OR stud*)) or ti,ab(“clinical trial” or 
“meta-analysis” or “multicenter study” or “multicenter study” or “prospective 
study”)) NOT ((EMB.EXACT(“case study”)) OR EMB.EXACT(“letter”) OR EMB.
EXACT(“editorial”) OR (ti,ab(“case study” or “letter” or “editorial”)))
EMBASE® 4070093*
S20 (S15 AND S18 AND S19) and (human(yes)) and (la.exact(“English”)) EMBASE® 32°






for part of 
your query
34°
*Duplicates are removed from the search, but included in the result count. °Duplicates are removed from the search and from the 
result count. With duplicates=41
Table 1:(Continued)
search terms relating to GB function to PPIs. 
The search was narrowed by applying filters to 
limit the studies only to the English language and 
human. The bibliographies of relevant studies 
were also screened to identify other relevant 
studies. The search results were downloaded 
and imported in reference management software 
“Zotero.”
Study selection
The studies were screened in abstract screening 
software “Rayyan QCRI“[9] by two researchers by 
title and abstracts, and discrepancies were resolved 
through discussion. Primary research studies and 
systematic reviews relevant to PPIs and GB function, 
reporting the effects of anti-secretary drugs on GB 
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motility and published in English, were included in 
our research. The inclusion and exclusion criteria 
are reported in full in Table 2 in Supplementary 
Materials.
The full texts were retrieved for all studies that 
met the inclusion criteria for the title and abstract 
screening. Full texts were screened using the 
same inclusion criteria as abstract screening 
but focused on identifying studies with clinically 
relevant outcomes. Two researchers independently 
conducted full-text screening and resolved the 
disagreements through discussion.
Data extraction
We planned to extract the relevant data into a 
pre-agreed Microsoft Excel template and resolve 
any disagreements by discussion. Where available, 
we planned to extract the following data for each 
eligible study: 
1. Study details: Study name, study design, year 
of publication, study duration, study setting, 
country, recruitment method, number of study 
centers, and inclusion and exclusion criteria
2. Participants characteristics: Age, sex, ethnicity, 
body weight, concomitant diseases, and the 
number of subjects in the intervention and 
control group
3. Interventions: Description of intervention and 
control treatment, dosage, regimen, and any 
concomitant medications
4. Outcomes: Primary and secondary outcomes 
specified and collected, time points reported, 
number of subjects with follow-up data, 
statistical analyses data, and adverse effects 
data.
We planned to evaluate the methodological 
quality of the included studies using the best 
available guidelines for each study design outlined 
in the library for health research reporting.[10] We 
planned to conduct a descriptive analysis from 
the included studies and synthesize the results 
narratively to identify common themes and gaps 
in the evidence.
Results
The database search of EMBASE, Medline, and 
Cochrane Central Register of Controlled Trials 
(CENTRAL) identified 44 citations, of which 
6 were duplicates, leaving 38 unique citations for 
screening [Table 3]. Two independent reviewers 
(MJ and MST) screened the titles and abstracts 
against the eligibility criteria shown in Table 2. 
Discrepancies were resolved through discussion. 
We assessed five full-text articles for eligibility 
using the same inclusion and exclusion criteria 
but found none to be eligible for inclusion into 
our review [Figure 1]. The reasons for exclusion 
are provided in the PRISMA flow diagram. 
Articles excluded based on full-text screening 
are listed in Table 4.
Table 2: Identification and inclusion/exclusion of studies
Description Inclusion Exclusion
Patient population • Adult and/or pediatric patients with poor 
GBEF (reduced gallbladder function)
• Patients with other diseases
• Animal/in vitro studies
Intervention PPIs All other interventions
Comparator Any or none N/A
Outcomes • Gallbladder ejection function
• Biliary-type pain
•  Blood tests, including serum alanine aminotransferase, aspartate aminotransferase, 
conjugated and unconjugated bilirubin, alkaline phosphatase, amylase, and lipase









Limits English language only; human only
Timespan No limits; all databases were searched from inception to April 30, 2020.
aRelevant SLRs and NMAs will be ordered and included study lists will be reviewed, to identify any additional relevant publications
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Table 3: Total number of studies identified 
from database searches






This is an empty systematic review as none of the 
studies met the eligibility criteria for inclusion in this 
review. However, we did identify one study single-
arm study conducted in 2006 to determine the 
effect of chronic PPI therapy on GB function.[11] The 
authors enrolled 21 healthy subjects for a 30 days 
trial by advertising in the newspaper and a 
university campus. Nineteen subjects completed 
the study. The investigators measured GBEF of 
each subject before commencing 40 mg once daily 
omeprazole. The GBEF was measured again on 
day 30. The authors concluded that PPI therapy 
was associated with reduced GB motility in healthy 
volunteers. Although this study provides some 
indication of the association between PPI and GB 
dysfunction, this study is subjected to high risk of 
bias and has several flaws including small sample 
size, no comparison group, short study duration, 
no randomization, and no blinding. In addition to 
the above, the study subjects were selected by 
advertising in the newspaper and on campus, which 
make this population less representative of the 
target population.
GB motility is vital for the health of the digestive 
system. Low GBEF causes irritation and 
inflammation of the GB walls, which, in turn, can 
lead to serious diseases including GB cancer. Hence, 
it is essential to maintain the GB health. PPIs are 





















n Records identified through
Medline and Embase searching
(n = 39)
Additional records identified
through CENTRAL (n = 5)


















Figure 1: PRISMA flow diagram
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evidence that change in lifestyle can improve GERD 
symptoms.[12] However, the patients who require 
PPIs should receive the lowest effective dose[13] 
and that combining lifestyle interventions with PPIs 
provide better results.[14] Evidence suggests that 
most patients receiving twice-daily PPI therapy 
for GERD could be maintained on once-daily PPI 
or no acid suppression for 12 months of follow-
up.[15] In addition to this, the use of right PPI for 
specific symptoms would not only treat GERD 
more efficiently but will also reduce the economic 
burden on national health care. For instance, 
Javed et al. (2020)[6] reported that omeprazole 
lowered intragastric pH faster and the results lasted 
longer compared to lansoprazole.[16] The results 
were statistically significant; hence, it is advisable 
to administer omeprazole to GERD patients if 
the objective is to lower intragastric pH unless 
recommended otherwise by the physician.
We are confident that our search strategy was 
comprehensive, and we identified all the relevant 
literature. We did not apply any age limits and 
incorporated a variety of study designs in a bid to 
retrieve all relevant publications; however, none of 
the studies met the inclusion criteria. Far less research 
has been carried out to understand the effect of PPIs 
on GB function. Hence, there is an urgent need to 
design and conduct high-quality clinical studies to 
determine the association of various PPIs and GBEF.
Conclusion
There are no good quality studies determining the 
effect of PPIs on GB function. Given the common 
use of PPIs and their potential impact on GB 
function, there is an urgent need of conducting 
clinical studies to fill this gap in the literature.
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Supplementary Material
Search terms for Cochrane Library were “gallbladder” AND “proton-pump inhibitor*” retrieved 5 articles.
All three databases were searched from inception to April 30, 2020.
